EA201891732A1 - Биспецифичные связывающие белки для pd-l1 и kdr - Google Patents
Биспецифичные связывающие белки для pd-l1 и kdrInfo
- Publication number
- EA201891732A1 EA201891732A1 EA201891732A EA201891732A EA201891732A1 EA 201891732 A1 EA201891732 A1 EA 201891732A1 EA 201891732 A EA201891732 A EA 201891732A EA 201891732 A EA201891732 A EA 201891732A EA 201891732 A1 EA201891732 A1 EA 201891732A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- binding proteins
- bispecific binding
- kdr
- bispecific
- human
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662290350P | 2016-02-02 | 2016-02-02 | |
PCT/US2017/016230 WO2017136562A2 (fr) | 2016-02-02 | 2017-02-02 | Protéines de liaison bispécifiques pour pd-l1 et kdr |
Publications (1)
Publication Number | Publication Date |
---|---|
EA201891732A1 true EA201891732A1 (ru) | 2019-02-28 |
Family
ID=59501012
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201891732A EA201891732A1 (ru) | 2016-02-02 | 2017-02-02 | Биспецифичные связывающие белки для pd-l1 и kdr |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP3411068A4 (fr) |
JP (1) | JP2019506863A (fr) |
CN (1) | CN109310755A (fr) |
EA (1) | EA201891732A1 (fr) |
WO (1) | WO2017136562A2 (fr) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2978942A1 (fr) | 2015-03-13 | 2016-09-22 | Cytomx Therapeutics, Inc. | Anticorps anti-pdl1, anticorps anti-pld1 activables, et leurs procedes d'utilisation |
EP3630838A1 (fr) | 2017-06-01 | 2020-04-08 | CytomX Therapeutics, Inc. | Anticorps anti-pdl1 activables, et leurs procédés d'utilisation |
JP7145895B2 (ja) * | 2017-09-01 | 2022-10-03 | 四川科倫博泰生物医薬股▲フン▼有限公司 | 組換え二重特異性抗体 |
BR112020013854A2 (pt) * | 2018-02-28 | 2020-12-01 | Ap Biosciences, Inc. | proteínas bifuncionais que combinam bloqueio de ponto de verificação para a terapia alvejada |
CN111196855B (zh) * | 2018-11-19 | 2022-11-15 | 三生国健药业(上海)股份有限公司 | 抗egfr/pd-1双特异性抗体 |
CN111196856A (zh) * | 2018-11-19 | 2020-05-26 | 三生国健药业(上海)股份有限公司 | 抗her2/pd1双特异性抗体 |
EP3891182A4 (fr) | 2018-12-03 | 2022-08-17 | Immuneonco Biopharmaceuticals (Shanghai) Co., Ltd | Protéine de recombinaison ciblant pd-l1 et vegf |
CN109776683B (zh) * | 2019-03-19 | 2020-04-07 | 益科思特(北京)医药科技发展有限公司 | 一种双特异性抗体及其制备方法与应用 |
JP2022538237A (ja) * | 2019-06-24 | 2022-09-01 | ノバルティス アーゲー | B細胞成熟抗原を標的にする多重特異性抗体のための投与計画及び組み合わせ治療 |
CN110498857B (zh) * | 2019-08-09 | 2022-09-09 | 安徽瀚海博兴生物技术有限公司 | 一种抗vegf-抗pd1双特异性抗体 |
CN110563849B (zh) * | 2019-08-09 | 2022-09-09 | 安徽瀚海博兴生物技术有限公司 | 一种抗vegf-抗pd1双特异性抗体 |
WO2021026685A1 (fr) * | 2019-08-09 | 2021-02-18 | 安徽瀚海博兴生物技术有限公司 | Anticorps bispécifique anti-vegf-anti-pd1 ayant une structure d'un nouveau type |
CN110760517B (zh) * | 2019-10-09 | 2022-04-29 | 天津大学 | 拮抗pd-1骆驼抗体类似物ap基因及蛋白和应用 |
CN113563473A (zh) * | 2020-04-29 | 2021-10-29 | 三生国健药业(上海)股份有限公司 | 四价双特异性抗体、其制备方法和用途 |
CN113754772A (zh) * | 2020-06-02 | 2021-12-07 | 三生国健药业(上海)股份有限公司 | 一种抗pdl1×kdr的双特异性抗体 |
CN113754773A (zh) * | 2020-06-02 | 2021-12-07 | 三生国健药业(上海)股份有限公司 | 一种抗pd1×pdl1的双特异性抗体 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005051299A2 (fr) * | 2003-11-19 | 2005-06-09 | Dyax Corp. | Proteines de liaison aux metalloproteinases |
KR101479537B1 (ko) * | 2006-08-03 | 2015-01-07 | 백시넥스 인코포레이티드 | 항-il-6 모노클로날 항체 및 이의 용도 |
US7935345B2 (en) * | 2007-05-21 | 2011-05-03 | Children's Hospital & Research Center At Oakland | Monoclonal antibodies that specifically bind to and neutralize bacillus anthracis toxin, compositions, and methods of use |
US20140234340A1 (en) * | 2010-11-30 | 2014-08-21 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly |
JP5588086B2 (ja) * | 2011-04-19 | 2014-09-10 | メリマック ファーマシューティカルズ インコーポレーティッド | 単一特異性および二重特異性抗IGF‐1R抗体および抗ErbB3抗体 |
SG11201402603WA (en) * | 2011-11-28 | 2014-06-27 | Merck Patent Gmbh | Anti-pd-l1 antibodies and uses thereof |
CA2874144C (fr) * | 2012-05-31 | 2023-12-19 | Genentech, Inc. | Procedes de traitement du cancer au moyen d'antagonistes liant l'axe pd-1 et d'antagonistes de vegf |
US20150238601A1 (en) * | 2012-10-05 | 2015-08-27 | Kadmon Corporation, Llc | Treatment of ocular disorders |
CA2926478C (fr) * | 2012-10-05 | 2022-05-24 | Kadmon Corporation, Llc | Inhibiteurs de rho kinase |
US20160145355A1 (en) * | 2013-06-24 | 2016-05-26 | Biomed Valley Discoveries, Inc. | Bispecific antibodies |
US10519247B2 (en) * | 2013-11-01 | 2019-12-31 | Board Of Regents,The University Of Texas System | Targeting HER2 and HER3 with bispecific antibodies in cancerous cells |
HRP20220214T1 (hr) * | 2014-01-15 | 2022-04-29 | Kadmon Corporation, Llc | Imunomodulacijska sredstva |
-
2017
- 2017-02-02 JP JP2018540412A patent/JP2019506863A/ja active Pending
- 2017-02-02 WO PCT/US2017/016230 patent/WO2017136562A2/fr active Application Filing
- 2017-02-02 EA EA201891732A patent/EA201891732A1/ru unknown
- 2017-02-02 CN CN201780021304.8A patent/CN109310755A/zh active Pending
- 2017-02-02 EP EP17748163.7A patent/EP3411068A4/fr not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
CN109310755A (zh) | 2019-02-05 |
WO2017136562A2 (fr) | 2017-08-10 |
WO2017136562A3 (fr) | 2017-09-28 |
EP3411068A2 (fr) | 2018-12-12 |
JP2019506863A (ja) | 2019-03-14 |
EP3411068A4 (fr) | 2020-01-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201891732A1 (ru) | Биспецифичные связывающие белки для pd-l1 и kdr | |
CY1123163T1 (el) | Αντισωματα που δεσμευουν beta klotho επικρατεια 2 και μεθοδοι χρησης αυτων | |
EA201890285A1 (ru) | Антитела против pd-1, активируемые антитела против pd-1 и способы их применения | |
EA201890131A1 (ru) | Иммуномодуляция и лечение солидных опухолей антителами, которые специфически связывают cd38 | |
EA201892362A1 (ru) | Агонистические антитела, которые связываются с cd40 человека, и варианты их применения | |
EA201890145A1 (ru) | Антитела к фактору xi и способы их применения | |
EA201990912A1 (ru) | Анти-lag-3 антитела и их композиции | |
EA201890305A1 (ru) | Гуманизированные или химерные cd3-антитела | |
EA201791485A1 (ru) | Анти-cd47-антитела и их применения | |
EA201890790A1 (ru) | Связывающие pd-1 белки и способы их применения | |
NZ738008A (en) | Tigit-binding agents and uses thereof | |
EA201890453A1 (ru) | Анти-angptl8 антитела и их применение | |
EA201991720A1 (ru) | Антитела к альфа-синуклеину и их применения | |
EA201690167A1 (ru) | Гуманизованные или химерные антитела к cd3 | |
EA201891331A1 (ru) | Бипаратопные полипептиды - антагонисты передачи сигнала wnt в опухолевых клетках | |
EA201791093A1 (ru) | Антитела к cd47, способы и применение | |
EA202190609A1 (ru) | Антитела против hla-g, композиции, содержащие антитела против hla-g, и способы применения антител против hla-g | |
GEP20227343B (en) | Anti-lag3 antibodies and antigen-binding fragments | |
EA201790719A1 (ru) | Биспецифические моновалентные диатела, которые способны связывать cd19 и cd3, а также их применения | |
EA202091315A3 (ru) | Антитела человека, связывающиеся с g-белком rsv | |
EA201691541A1 (ru) | Новые анти-baff антитела | |
EA201991546A1 (ru) | Антигенсвязывающие белки против нейропилина и способы их применения | |
EA201892225A1 (ru) | АНТИТЕЛА К ФАКТОРУ Bb КОМПЛЕМЕНТА И ИХ ПРИМЕНЕНИЕ | |
EA201792220A1 (ru) | Опосредуемая антителом нейтрализация вируса чикунгунья | |
EA201792561A1 (ru) | Антитела, нацеленные на морфогенетический белок кости 9 (bmp9), и способы их применения |